Karen A. Dawes, Director at REPLIGEN CORP (RGEN), sold 29,430 shares at $149.18 ($4.4M) on 2022-05-25, disclosed to the SEC on 2022-05-26.
Seasonal sale ($4.4M) by Director — this insider has traded RGEN in May in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $149.18 | 2,576 | $384K | 8.7% |
| 2 | $149.18 | 2,576 | $384K | 8.7% |
| 3 | $150.19 | 7,677 | $1.2M | 26.0% |
| 4 | $150.19 | 7,677 | $1.2M | 26.0% |
| 5 | $151.14 | 1,845 | $279K | 6.3% |
| 6 | $151.14 | 1,845 |
| $279K |
| 6.3% |
| 7 | $152.14 | 1,875 | $285K | 6.4% |
| 8 | $152.14 | 1,875 | $285K | 6.4% |
| 9 | $152.84 | 742 | $113K | 2.6% |
| 10 | $152.84 | 742 | $113K | 2.6% |
| Total | $150.51 avg | 29,430 | $4.4M | 100% |
| Filing → |
| RGEN | SELL | 2023-08-30 | $146K | — | Filing → |
| RGEN | SELL | 2022-09-09 | $352K | — | Filing → |
| RGEN | SELL | 2021-11-12 | $2.5M | — | Filing → |